A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough

Trial Profile

A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 27 May 2016 Status changed from active, no longer recruiting to completed.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 16 May 2016 Data from the second cohort of this trial are expected to be presented at a medical/scientific conference in the second half of 2016, according to an Afferent Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top